Clinical Trials

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06842498 2026-05-22

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

75 enrolled

Prostatic Neoplasms

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07028853 2026-05-22

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT07114601 2026-05-22

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07213674 2026-05-22

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07529717 2026-05-22

CRIUS-1

42 enrolled

Prostatic Neoplasms

NCT07493512 2026-05-20

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

40 enrolled

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07600554 2026-05-20

SWAP

20 enrolled

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

700 enrolled

Prostatic Neoplasms

NCT05348876 2026-05-18

A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)

Phase 4 Recruiting

50 enrolled

Prostatic Neoplasms

NCT05800665 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

210 enrolled

Prostatic Neoplasms

NCT03437941 2026-05-15

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Terminated

39 enrolled 43 charts

EndocrineGenitourinaryNET

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

Phase 1/2 Completed

98 enrolled

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT06172478 2026-05-15

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 2 Recruiting

740 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06255041 2026-05-15

Detection of Cancer in Breath Samples by Trained Detection Dogs

Completed

1,386 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

707 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Neoplasms, Prostatic Neoplasms

NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Available

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT07564102 2026-05-15

dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy

Phase 1/2 Not yet recruiting

30 enrolled

Phase 1/2 Not yet recruiting

Prostatic Neoplasms

NCT07590934 2026-05-15

PROSPECTOR

152 enrolled

Prostatic Neoplasms

NCT05413850 2026-05-14

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

82 enrolled

Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT06056830 2026-05-14

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT06613100 2026-05-14

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

40 enrolled

Prostatic Neoplasms

NCT06970847 2026-05-14

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT07285694 2026-05-14

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

190 enrolled

Phase NA Active not recruiting

Neoplasm Metastasis, Prostatic Neoplasms

NCT04905069 2026-05-12

SABRE

500 enrolled

Neoplasms, Prostatic Neoplasms

NCT05919264 2026-05-12

FOG-001 in Locally Advanced or Metastatic Solid Tumors

CNSGastrointestinalGenitourinaryGynecologicSarcoma

595 enrolled

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06451614 2026-05-12

HYDROSPACE

Phase NA Active not recruiting

230 enrolled

Prostatic Neoplasms

NCT06511141 2026-05-12

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Phase NA Recruiting

150 enrolled

Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive

NCT06604442 2026-05-12

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Phase 4 Completed

62 enrolled 15 charts

Prostatic Neoplasms

NCT06879041 2026-05-12

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT07581184 2026-05-12

BActinium-1

138 enrolled

Prostatic Neoplasms

NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Phase 1/2 Completed

127 enrolled 16 charts

Prostatic Neoplasms

NCT01946204 2026-05-11

SPARTAN

1,207 enrolled 15 charts 1 FDA

Prostatic Neoplasms

NCT02257736 2026-05-11

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT02489318 2026-05-11

TITAN

1,052 enrolled 13 charts 1 FDA

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-05-11

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Prostatic Neoplasms

NCT04122976 2026-05-11

DAROL

Active not recruiting

805 enrolled

Prostatic Neoplasms

NCT06257264 2026-05-11

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

258 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02123758 2026-05-08

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Active not recruiting

57 enrolled

Prostatic Neoplasms

NCT02531516 2026-05-08

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled